ZEALAND Proposed acquisition of Chapter-11-protected US company:
Zealand announced this morning that it has submitted a bid to acquire �substantially all assets� of Valeritas, a US-based commercial-stage company which is commercializing an insulin delivery device called V-Go, a all-in-one basal-bolus option for adults that is used like a daily patch and eliminates multiple shots. In December, the company announced that it was facing a temporary disruption in supply of its product, making it unable to ship it any longer. Valeritas said it had cash until February 2020 and as it was expected supply disruption to continue, it said it would explore all strategic alternatives.Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.